Company Filing History:
Years Active: 2023
Title: John Short - Innovator in Retroviral and Lentiviral Vectors
Introduction
John Short is a notable inventor based in London, GB. He has made significant contributions to the field of biotechnology, particularly in the development of viral vectors. His work focuses on enhancing the activation of T-cells and Natural Killer cells, which are crucial for immune responses.
Latest Patents
John Short holds a patent for a retroviral and lentiviral vector. This invention provides a viral envelope that includes a mitogenic T-cell activating transmembrane protein. The protein consists of a mitogenic domain that binds a mitogenic tetraspanin and a transmembrane domain. Importantly, the mitogenic T-cell activating transmembrane protein is not part of a viral envelope glycoprotein. This innovation allows for the activation of T-cells and Natural Killer cells when transduced by the viral vector.
Career Highlights
John Short is currently associated with Autolus Limited, a company that specializes in developing innovative T-cell therapies. His expertise in viral vectors has positioned him as a key player in advancing therapeutic options for various diseases.
Collaborations
Some of his notable coworkers include Vijay Peddareddigari and Richard Beswick. Their collaborative efforts contribute to the ongoing research and development in the field of immunotherapy.
Conclusion
John Short's work in retroviral and lentiviral vectors represents a significant advancement in biotechnology. His innovative approach to T-cell activation has the potential to impact therapeutic strategies in immunology.